



## **PROGLIF-F TABLETS**

*Issue V, No.15., 2026*

### **Effectiveness of Empagliflozin-Linagliptin Fixed-Dose Combination on Chronic Kidney Disease Outcomes in Patients with Type 2 Diabetes in a Real-World Setting**

*2025\_Sanyal.D et.al\_FDC Empa + Lina on CKD with T2DM pts\_Cureus*

- Empagliflozin, provides additional kidney protection beyond glycemic control, while linagliptin is renal-safe and associated with reductions in albuminuria. This retrospective study aimed to evaluate the long-term outcomes (at least one year) for CKD and T2DM with the fixed-dose combination (FDC) of empagliflozin and linagliptin in sodium glucose cotransporter-2 inhibitor (SGLT2-i)-naïve T2DM subjects who were previously uncontrolled on a dipeptidyl-peptidase-4 inhibitor (DPP4-i)-based regimen.
- This real-world retrospective study was conducted on a cohort of patients with type 2 diabetes mellitus (T2DM) patients (N=433) receiving routine care at two tertiary-care clinic settings in eastern India. Glycemic control and renal parameters, including estimated glomerular filtration rate (eGFR), eGFR slope, and changes in urine albumin-creatinine ratio (UACR), were evaluated.
- The primary objective of this study is to evaluate changes in albuminuria and renal function over 12 months of treatment. Secondary objectives include assessing changes in glycemic control, body weight, and blood pressure.
- A significant reduction in glycated haemoglobin (HbA1c) of 1.5% was observed from a baseline mean of  $8.3 \pm 1.7\%$ , reduction in mean UACR of 142.9 mg/g from 207.8 mg/g at baseline to 64.9 mg/g at 12 months, along with a mean body-weight reduction of 3.3 kg over 12 months of combination therapy.
- FDC of empagliflozin and linagliptin for at least 12 months in T2DM patients previously uncontrolled on a DPP4-i-based regimen was associated with reductions in albuminuria and improvement in eGFR slope.

**The empagliflozin-linagliptin FDC provided effective glycemic control, early achievement of target HbA1c, reduction in albuminuria with additional clinical benefits of weight loss and blood pressure reduction.**

